In 2017,Lee, Eun; An, Ying; Kwon, Junhee; Kim, Keun Il; Jeon, Raok published 《Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors》.Bioorganic & Medicinal Chemistry published the findings.Product Details of 15366-34-4 The information in the text is summarized as follows:
A strong relationship between abnormal functions of Aurora kinases and tumorigenesis has been reported for decades. Consequently, Aurora kinases serve as potential targets for anticancer agents. Here, we identified aminobenzothiazole derivatives as novel inhibitors of Aurora B kinase through bioisosteric replacement of the previous inhibitors, aminobenzoxazole derivatives Most of the urea-linked aminobenzothiazole derivatives showed potent and selective inhibitory activity against Aurora B kinase over Aurora A kinase. Mol. modeling indicated that compound I bound well to the active site of Aurora B kinase and formed the essential hydrogen bonds. The potent compounds, I and II, were selected, and their biol. effects were evaluated using HeLa cell lines. It was found that these compounds inhibited the phosphorylation of histone H3 at Ser10 and induced G2/M cell cycle arrest. We suggest that the reported compounds have the potential to be further developed as anticancer therapeutics. In addition to this study using Methyl 1H-pyrazole-3-carboxylate, there are many other studies that have used Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Product Details of 15366-34-4) was used in this study.
Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Product Details of 15366-34-4
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics